impact factor
logo
 

Review

 

One year in review 2021: systemic lupus erythematosus


1, 2, 3, 4, 5, 6

 

  1. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. francesca3ntin@gmail.com
  2. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  3. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  4. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, and Department of Medical Biotechnologies, University of Siena, Italy.
  5. Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy.
  6. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

CER14665
2021 Vol.39, N°2
PI 0231, PF 0241
Review

Free to view
(click on article PDF icon to read the article)

PMID: 33843578 [PubMed]

Received: 26/03/2021
Accepted : 02/04/2021
In Press: 09/04/2021
Published: 09/04/2021

Abstract

In 2020 many contributions have been produced on SLE. Our critical digest of the recent literature will be focused on genetic factors that contribute to the development of the disease, novel potential therapeutic targets (including IL-23, IL-17, interferons and JAKs), diagnostic and prognostic biomarkers, classification criteria, clinical manifestations and comorbidities. We will then present new treatment options (with a special focus on belimumab, anifrolumab, tacrolimus, voclosporin and EULAR/ERA-EDTA recommendations for the management of LN) and treat-to-target strategy. Lastly, we will concentrate on some of the aspects that influence patients’ disease perception and quality of life.

Rheumatology Article